Phathom Pharmaceuticals, Inc. Stock Price, News & Analysis

Phathom Pharmaceuticals (Nasdaq: PHAT) has submitted two new drug applications (NDAs) to the FDA for vonoprazan-based therapies aimed at treating Helicobacter pylori infection in adults. The vonoprazan triple therapy and dual therapy show superior eradication rates compared to current treatments. If approved, Phathom expects to launch these therapies in the U.S. in the latter half of 2022. The submissions follow positive results from the pivotal Phase 3 PHALCON-HP trial, the largest U.S. study for H. pylori. The FDA has also granted these therapies Fast Track designation and qualified infectious disease product status.

Phathom Pharmaceuticals (Nasdaq: PHAT) announced that its executives, including President and CEO Terrie Curran, will engage in a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021, at 11:00 a.m. ET. The company will also hold one-on-one meetings during the virtual conference from September 9-15, 2021. Phathom focuses on developing innovative treatments for gastrointestinal diseases, notably vonoprazan, a potassium competitive acid blocker in late-stage development for acid-related disorders. Recordings will be available for 90 days following the event.

Phathom Pharmaceuticals (Nasdaq: PHAT) reported Q2 2021 financial results, revealing a net loss of $36.6 million, up from $21.1 million YoY. R&D expenses rose to $21.6 million due to increased clinical trial and CMC costs. General and administrative expenses also climbed to $13.7 million. The company anticipates pivotal Phase 3 data for vonoprazan in erosive esophagitis by October 2021 and Phase 2 data in Q1 2022. Additionally, Phathom is set to submit NDAs for vonoprazan-based regimens for H. pylori in September 2021, with cash reserves of $209.7 million sufficient into Q4 2022.

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) announced the unexpected passing of its chairman and founder, Dr. Tachi Yamada, on August 4, 2021, at his home in Seattle, Washington. The company expressed deep condolences to Dr. Yamada's family, highlighting his significant contributions to both Phathom and the field of gastroenterology. Dr. Yamada was recognized as a transformative figure in his industry. Phathom, specializing in treatments for gastrointestinal diseases, is advancing its late-stage development of vonoprazan, a novel treatment for acid-related disorders.

Phathom Pharmaceuticals (Nasdaq: PHAT) will participate in the virtual BMO Biopharma Spotlight Series on August 12, 2021. Terrie Curran, the company's President and CEO, will be part of the "Innovation in GI" panel discussion at 10:50 a.m. ET. Additionally, Phathom management will engage in one-on-one meetings during the event. An on-demand webcast will be accessible on their website for 30 days post-event. Phathom specializes in developing treatments for gastrointestinal diseases and has in-licensed vonoprazan, a late-stage P-CAB treatment for acid-related disorders.

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) has announced that its management team will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 10:00 a.m. ET. The conference runs from June 1-4, 2021, during which management will also engage in one-on-one meetings. Investors can access a live webcast and archived recording via the Phathom website, available for 90 days post-event. Phathom focuses on developing treatments for gastrointestinal diseases, with exclusive rights to vonoprazan for acid-related disorders.

Phathom Pharmaceuticals (NASDAQ: PHAT) reported a positive Phase 3 trial outcome for vonoprazan in treating H. pylori infections, meeting all primary and secondary endpoints. The FDA granted additional qualified infectious disease product (QIDP) designations to vonoprazan-based therapies. The company is set to submit New Drug Applications (NDAs) in Q4 2021. Despite a net loss of $34.8 million in Q1 2021, cash reserves of $238 million are projected to fund operations through Q4 2022.

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) announced its participation in the Bank of America Securities 2021 Virtual Healthcare Conference on May 13, 2021, at 8:45 a.m. ET. Members of the management team will engage in a fireside chat and conduct one-on-one meetings. Interested parties can access the live webcast and a subsequent recording on Phathom's website, available for 90 days post-event. The company focuses on developing treatments for gastrointestinal diseases, including its late-stage candidate, vonoprazan, a novel potassium competitive acid blocker.

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) announced successful results from its pivotal Phase 3 trial, PHALCON-HP, which tested vonoprazan-based treatment regimens for H. pylori eradication. Both vonoprazan triple therapy (84.7% eradication rate) and dual therapy (78.5%) surpassed the standard lansoprazole triple therapy (78.8%). Phathom plans to submit New Drug Applications (NDA) by Q4 2021. The trial highlighted the need for improved therapies facing rising antibiotic resistance. The safety profile of vonoprazan was comparable to existing treatments, with adverse event rates generally low.